<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23184" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperkeratosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farci</surname>
            <given-names>Fabiola</given-names>
          </name>
          <aff>Pisa University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahabal</surname>
            <given-names>Gauri D.</given-names>
          </name>
          <aff>Christian Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fabiola Farci declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gauri Mahabal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23184.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperkeratosis refers to the increased thickness of the stratum corneum, the outer layer of the skin. It is most frequently due to chronic physical or chemical damage such as friction or the use of aggressive soaps but can also derive from chronic inflammation or a side-effect of different drugs, including chemotherapy. This activity reviews the evaluation and treatment of hyperkeratosis and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of hyperkeratosis.</p></list-item><list-item><p>Summarize the major histologic forms of hyperkeratosis.</p></list-item><list-item><p>Review the different pathologies that can manifest with hyperkeratosis.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure the appropriate diagnosis and treatment is selected for patients with hyperkeratosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23184&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23184">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23184.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hyperkeratosis refers to the increased thickness of the stratum corneum, the outer layer of the skin. Stratum corneum is composed of multiple layers of keratinocyte bodies that, during maturation, produced keratin and subsequently have lost their nucleus and cytoplasmic organelles. The result is a basketweave appearance of anucleate keratinocytes that protect the underlying cells during maturation.</p>
        <p>Hyperkeratosis is subclassified as orthokeratotic or parakeratotic.&#x000a0;Orthokeratotic hyperkeratosis refers to the thickening of the keratin layer with preserved keratinocyte maturation, while parakeratotic hyperkeratosis shows retained nuclei as a sign of delayed maturation of keratinocytes. Hyperkeratosis can be associated with&#x000a0;dyskeratosis.&#x000a0;It&#x000a0;represents a premature (keratinocytes that are located below the granular cell layer) or abnormal keratinization of individual keratinocytes.</p>
        <p>Hyperkeratosis, associated with&#x000a0;other abnormalities in the skin biopsy, can be a key to the final histological diagnosis. Epidermal hypertrophy is a benign alteration of the skin that presents with acanthosis (increased thickness of the keratinocyte layers) and hyperkeratosis.</p>
      </sec>
      <sec id="article-23184.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Increased thickness of the stratum corneum can be due to several exogenous or endogenous processes and is related to increased production of keratin in the outer portion of the skin layer. In the majority of cases in clinical practice, it is mostly due to chronic physical or chemical damage such as friction or the use of aggressive soaps (especially those with a basic pH) but can also derive from chronic inflammation or a side-effect of different drugs, including chemotherapy.<xref ref-type="bibr" rid="article-23184.r1">[1]</xref><xref ref-type="bibr" rid="article-23184.r2">[2]</xref>&#x000a0;</p>
        <p>Hyperkeratosis happening in the context of a&#x000a0;reactive state of the skin is the prototypical result of dermatitis. Another cause of hyperkeratosis is a nutritional deficit, especially in vitamin A deficiency,&#x000a0;causing phrynoderma,&#x000a0;where the skin can exhibit keratin plugs and hyperkeratosis&#x000a0;of the hair follicles, atrophy, and squamous metaplasia of the sebaceous glands.<xref ref-type="bibr" rid="article-23184.r3">[3]</xref><xref ref-type="bibr" rid="article-23184.r4">[4]</xref><xref ref-type="bibr" rid="article-23184.r5">[5]</xref></p>
      </sec>
      <sec id="article-23184.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence is unknown, as hyperkeratosis is the histopathologic aspect of many different pathologies, both benign and malignant.</p>
      </sec>
      <sec id="article-23184.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The skin is composed of three layers: the epidermis, the dermis (composed of the superficial papillary and deeper reticular dermis), and the hypodermis. The skin has structural differences among the different areas of the body in terms of epidermal and dermal thickness, distribution of appendages, and pigmentation. The epidermis is composed of multiple layers&#x000a0;of maturing keratinocytes:&#x000a0;the basal layer (stratum basale), the squamous layer (stratum spinosum), the granular layer (stratum&#x000a0;granulosum), and the cornified layer (stratum&#x000a0;corneum). This stratified epithelium is in a constant process of self-renewing and exfoliation that takes 20-40 days to complete. The cells in the outer layer are the most differentiated in the keratinocyte line, composed almost entirely of keratin lamels of high molecular weight, and those are the ones that undergo desquamation, completing the maturation cycle.</p>
        <p>When the epidermis is exposed to repetitive injury, it usually elicits an increased proliferative rate of the keratinocytes and accelerates their maturation. Keratinocytes also tend to produce more keratin, thus increasing the stratum corneum's thickness.&#x000a0;</p>
        <p>Injury to the epidermis, if acute, tends to result in&#x000a0;edema, also called spongiosis. This is seen as a clear space&#x000a0;between keratinocytes. Severe edema can cause the formation of intraepidermal vesicles as extracellular fluid accumulation between keratinocytes.&#x000a0;If the process becomes chronic, the edema regresses, and the epidermis becomes&#x000a0;hyperplastic as&#x000a0;a response to the chronic insult. Epidermal hyperplasia is&#x000a0;seen as a thickening of the epidermis and elongation of the rete ridges (called acanthosis), accompanied by ortho or para-hyperkeratosis.&#x000a0;These are the typical transition phases of acute to chronic spongiotic dermatitis such as eczema.</p>
        <p>Genetic mutations resulting in hyperkeratosis is seen in ichthyoses and keratoderma. There are several damages in keratin-encoding genes such as&#x000a0;KRT1 and&#x000a0;KRT10,<italic toggle="yes">&#x000a0;</italic>which&#x000a0;cause defects in keratin structure. Defective keratin causes irregular aggregates of intermediate filaments, which leads to cellular collapse and blistering. The barrier function is then compromised, and the skin reacts with compensatory hyperproliferation, which leads to hyperkeratosis.</p>
      </sec>
      <sec id="article-23184.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Mechanical hyperkeratosis: This is characterized by&#x000a0;increased keratinocyte activity&#x000a0;mainly due to&#x000a0;chronic pressure or friction on the skin. Lesions are benign demarcated hyperkeratotic lesions, mainly corn and callus. The presence of a central&#x000a0;conical core distinguishes a corn&#x000a0;from a callus. Corns are subtyped into hard corn (heloma durum) and soft corn (heloma molle). Both show dense hyperkeratotic stratum corneum with mild acanthosis, variable hypergranulosis, and collagenization of the superficial dermis with variable mucin deposition. There&#x000a0;is usually no inflammatory infiltrate accompanying the lesion.&#x000a0;</p>
        <p>Psoriasis and psoriasiform dermatitis: It shows perivascular aggregates of lymphocytes in the dermal-epidermal junction with focal migration&#x000a0;of leukocytes (neutrophils, lymphocytes) into the epidermis. There is increased epidermal proliferation and elongation of rete ridges giving an undulating appearance to the epidermis (papillomatosis) with or without spongiosis. The altered differentiation of&#x000a0;keratinocytes results in hyperkeratosis with parakeratosis. Psoriasis also shows the formation of microabscesses by small aggregates of neutrophils in the upper epidermis (pustules) or in the&#x000a0;stratum corneum (Munro microabscesses).&#x000a0;</p>
        <p>Interface and lichenoid dermatitis: Dense aggregates of lymphocytes along the dermal-epidermal junction associated&#x000a0;with vacuolation of basal keratinocytes.<xref ref-type="bibr" rid="article-23184.r6">[6]</xref>&#x000a0;There is dyskeratosis, hyperkeratosis, and is sometimes associated with&#x000a0;hypergranulosis.&#x000a0;</p>
        <p>Verrucae vulgaris and plana&#x000a0;are characterized by&#x000a0;marked hyperkeratosis, papillomatosis, and acanthosis. A typical feature is the presence of koilocytes, cells infected with papillomavirus which have structural changes like&#x000a0;perinuclear halos and keratohyalin granules. Koilocytes can be absent in older lesions, but when present, are located in the&#x000a0;upper stratum spinosum or granulosum.&#x000a0;Parakeratosis may be present.</p>
        <p>Seborrheic keratosis features marked hyperkeratosis, papillomatosis, and&#x000a0;acanthosis. Pseudo-cysts and horn cysts are frequently present. There may be lymphocytic infiltrate and pigmentation as secondary features when&#x000a0;irritated or inflamed.&#x000a0;</p>
        <p>The ichthyoses are a group of diseases caused by altered keratinization. The most common forms are ichthyosis vulgaris, X-linked, congenital, and epidermolytic&#x000a0;hyperkeratosis.<xref ref-type="bibr" rid="article-23184.r7">[7]</xref>&#x000a0;They can be hereditary&#x000a0;or acquired&#x000a0;during life.<xref ref-type="bibr" rid="article-23184.r8">[8]</xref><xref ref-type="bibr" rid="article-23184.r9">[9]</xref>&#x000a0;All of the forms show a defective epidermal barrier that&#x000a0;induces hyperkeratosis, skin scaling, and inflammation.</p>
        <p>Squamous&#x000a0;cell carcinoma (SCC) is a neoplastic proliferation of atypical keratinocytes, restricted only to the epidermis (SCC in situ or Bowen's disease) or infiltrating the dermis (infiltrative SCC). Classic features are hyper-parakeratosis and loss of the granular layer.</p>
      </sec>
      <sec id="article-23184.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>As previously said, hyperkeratosis can be the result of different pharmaceutical compounds&#x000a0;mainly used for oncologic treatments. Hyperkeratotic drug reaction occurs commonly with&#x000a0;tyrosine kinase inhibitors, cytotoxic chemotherapeutic agents, and immunomodulators or immune checkpoint inhibitors.<xref ref-type="bibr" rid="article-23184.r10">[10]</xref><xref ref-type="bibr" rid="article-23184.r11">[11]</xref><xref ref-type="bibr" rid="article-23184.r12">[12]</xref><xref ref-type="bibr" rid="article-23184.r13">[13]</xref>&#x000a0;The disruption of epidermal homeostasis alters the keratinocyte differentiation process or even interacts with the keratinocyte survival mechanism. Commonly described types of reactions include hand-foot&#x000a0;hyperkeratosis,&#x000a0;palmoplantar keratoderma, psoriasis, keratosis pilaris, pityriasis rubra pilaris, Grover's disease, and contact dermatitis with hyperkeratosis.<xref ref-type="bibr" rid="article-23184.r1">[1]</xref></p>
        <p>BCR-ABL inhibitors (mainly nilotinib and dasatinib) are commonly used for ontological target therapy, and the cutaneous side effects are only second to the hematologic sequelae. They are usually transitory and not severe. The most common dermatological side effect is a&#x000a0;pruritic skin rash, while&#x000a0;chronic dermatological side effects include psoriasis, lichenoid hyperkeratosis, pityriasis, and others.<xref ref-type="bibr" rid="article-23184.r14">[14]</xref><xref ref-type="bibr" rid="article-23184.r15">[15]</xref><xref ref-type="bibr" rid="article-23184.r16">[16]</xref></p>
        <p>Multikinase-inhibitors (VEGF,&#x000a0;PDGFR, EGFR, KIT, RET, Flt3, and RAF) affect the skin&#x000a0;homeostasis and give rise to many different cutaneous manifestations, mainly with hyperkeratosis&#x000a0;in the form of hyperkeratotic hand-foot skin reaction.<xref ref-type="bibr" rid="article-23184.r14">[14]</xref>&#x000a0;Hyperkeratosis occurs in the sites of friction or pressure, mainly soles, causing pain and limitation of the daily activities.<xref ref-type="bibr" rid="article-23184.r17">[17]</xref><xref ref-type="bibr" rid="article-23184.r18">[18]</xref></p>
        <p>Inhibition of the RAF pathway&#x000a0;can lead to paradoxical MAPK activation and&#x000a0;induce dimerization of RAF isomers. Keratinocyte proliferation is characteristic of B-RAF inhibitors, causing a broad spectrum of epidermal toxicities ranging from a verrucal reaction to squamous cell carcinoma. The use of the RAF-pathway inhibitor induces the rapid appearance of keratinocyte malignancies, mainly squamous cell carcinomas of the skin, even within the first week&#x000a0;after the starting them.<xref ref-type="bibr" rid="article-23184.r19">[19]</xref>&#x000a0;Those compounds, instead of actually inducing skin cancers, can reveal and facilitate the genetic events in the oncogenesis of keratinocytes. Characteristically, the verrucous lesions lack viral infection and the cytopathic viral changes seen in histology, and the keratinocyte appears minimally to mildly atypical. The epidermis shows only acanthosis and hyperkeratosis.&#x000a0;Experimental treatment with&#x000a0;downstream inhibition of the MAPK pathway (MEK-RAF blockade)&#x000a0;greatly reduces the&#x000a0;impact of this lesion during treatment.<xref ref-type="bibr" rid="article-23184.r20">[20]</xref></p>
        <p>The&#x000a0;dermo-epidermal changes related to&#x000a0;tattoo procedures can elicit skin reactions with hyperkeratosis patterns.<xref ref-type="bibr" rid="article-23184.r21">[21]</xref><xref ref-type="bibr" rid="article-23184.r22">[22]</xref><xref ref-type="bibr" rid="article-23184.r23">[23]</xref>&#x000a0;The pathogenesis is not clear, and etiology is probably multifactorial involving the local trauma, inflammatory reaction, ink composition, UV exposure, and genetic predisposition.&#x000a0;<xref ref-type="bibr" rid="article-23184.r24">[24]</xref><xref ref-type="bibr" rid="article-23184.r23">[23]</xref>&#x000a0;Of all dyes used for tattooing procedures, red dyes cause allergic contact dermatitis and characteristic patterns of plaques, hyperkeratosis, ulcerating reactions, urticaria, and skin rashes.</p>
      </sec>
      <sec id="article-23184.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Hyperkeratosis is a histopathological term defining a thickened stratum corneum and may be present in many different skin conditions, with many possible overlaps. History and clinical evaluation are key, and the main goal is to collect as much information as possible and discern which cases require a histopathological diagnosis to direct the most appropriate treatment.</p>
        <p>The history comprises the age of the patient, family history, exposure to toxic substances, drugs,&#x000a0;occupational duties, anamnesis of the current lesion, concomitant pathologies, and treatments.&#x000a0;In those patients where the&#x000a0;diagnosis was already established, it is appropriate to&#x000a0;reevaluate it, monitor&#x000a0;progression and complications following the treatment.</p>
        <p>The physical examination must be thorough to exactly understand the extent of the disease. Except for localized disease, it is important to inspect&#x000a0;the entire skin surface, including&#x000a0;scalp, eyelids, ears, perineum and genital mucosa,&#x000a0;hair, and nails. The&#x000a0;lesion should be described in terms of color, texture, shape, and distribution. Surrounding skin should be examined as well to detect the presence of generalized xerosis (dryness), seborrhea, hyper or hypohidrosis (sweating), texture, photoaging such as lentigines, actinic purpura, rhytides.&#x000a0;</p>
        <p>Small folliculocentric keratotic nodules can be found in cases of keratosis pilaris, where papules are&#x000a0;centered on small hair follicles, and it can be associated with erythema. On close examination, it is possible to recognize a small coiled hair beneath the papule formed by a keratin plug.&#x000a0;&#x000a0;</p>
        <p>Scaling is an important finding in cases of hyperkeratosis. Scales may&#x000a0;be described as&#x000a0;soft, rough, greyish, bran-like, and so on.&#x000a0;Crusts should not be confused with scale as it is the result of dried fluid on the&#x000a0;epidermis (serum, blood, pus, or a combination of those) and not thickening of the epidermis. Lichenification is a thickening of the skin and results from chronic injuries such as repetitive scratching. It is&#x000a0;present in most chronic eczematous or neurogenic processes.</p>
      </sec>
      <sec id="article-23184.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Dermoscopy is noninvasive and allows&#x000a0;visualization of the skin structures in the epidermis, dermo-epidermal junction, and&#x000a0;superficial dermis.</p>
        <p>A biopsy is essential&#x000a0;in cases in which the clinical setting is overlapping with different entities having&#x000a0;distinctive histopathologic&#x000a0;findings. For an ideal full-thickness biopsy, it is important to include the hypodermis. This can be&#x000a0;performed with a simple&#x000a0;3 mm punch that&#x000a0;minimizes scarring in the affected area. Any smaller size is at risk of being non-diagnostic.</p>
        <p>Patch tests&#x000a0;can be useful for identifying the causative allergen if an allergic dermatitis is suspected. Clinical clues are the presence of persistent, pruritic, eczematous eruptions in which any other identifiable cause has been excluded.&#x000a0;If the patient tests positive, they should be&#x000a0;encouraged to avoid the specific allergen. A follow-up after a few weeks of allergen avoidance is strongly recommended.</p>
      </sec>
      <sec id="article-23184.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Basic skincare measures are important to prevent excessive&#x000a0;dryness and to encourage exfoliation. Those remedies include soaps with skin-specific pH, soap-free cleansers, and avoidance of hot baths.&#x000a0;Emollients and topical keratolytic agents (lactic acid, salicylic acid, urea) should be advised to be applied over affected areas at the appropriate times.</p>
        <p>Sharp debridement is helpful in benign hyperkeratoses such as callus and corns to reduce the pressure and the amount of hyperkeratotic tissue. A chisel blade may be used to remove the keratin plug, providing relief to the area.&#x000a0;</p>
        <p>Surgical procedures have limited relevance in the treatment of hyperkeratosis. In cases of untreatable plantar keratosis with significant daily limitation, skin grafts with rotation skin flap have been demonstrated effective.<xref ref-type="bibr" rid="article-23184.r25">[25]</xref><xref ref-type="bibr" rid="article-23184.r26">[26]</xref>&#x000a0;</p>
        <p>Corticosteroids are the treatment of choice for inflammation-driven diseases such as lichen planus or psoriasis. Topical application is the best choice for localized disease. Topical applications should last&#x000a0;one to two weeks.</p>
        <p>Immunosuppressant or immunomodulators (cyclosporin, hydroxychloroquine, mycophenolate mofetil, sulfasalazine, alefacept, efalizumab) can be used in severe recurrent cases.</p>
        <p>Topical calcineurin inhibitors (tacrolimus or pimecrolimus) can also be used.</p>
        <p>Retinoids, topical or oral-based, are&#x000a0;used in disorders of keratinization such as ichthyoses, keratosis folliculitis, and psoriasis.&#x000a0;Topical administration is variable and must be evaluated in the appropriate clinical context; treatment usually lasts&#x000a0;8 to 12 weeks.</p>
        <p>Combination treatments with lasers (e.g., pulsed-dye laser, 755-nm alexandrite laser, 810-nm diode laser, 1064-nm Nd:YAG laser) and microdermabrasion are noninvasive techniques currently under approval for different hyperkeratotic diseases.</p>
      </sec>
      <sec id="article-23184.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The overall differential diagnosis for&#x000a0;hyperkeratosis is extremely broad and includes benign dermatological diseases as well as malignant ones. Overlapping clinical features make the diagnosis and workup challenging. A correct anamnesis, patient examination, and the appropriate use of skin biopsy are useful for the differential diagnosis.</p>
        <p>Differential diagnosis of hyperkeratosis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Callus and Corns</p>
          </list-item>
          <list-item>
            <p>Keratosis plantare</p>
          </list-item>
          <list-item>
            <p>Chronic folliculitis</p>
          </list-item>
          <list-item>
            <p>Atopic dermatitis</p>
          </list-item>
          <list-item>
            <p>Psoriasis and psoriasiform dermatitis</p>
          </list-item>
          <list-item>
            <p>Lichen planus and lichenoid dermatitis</p>
          </list-item>
          <list-item>
            <p>Keratosis pilaris</p>
          </list-item>
          <list-item>
            <p>Ichthyoses</p>
          </list-item>
          <list-item>
            <p>Seborrheic keratosis</p>
          </list-item>
          <list-item>
            <p>Actinic keratosis</p>
          </list-item>
          <list-item>
            <p>Keratoacanthoma</p>
          </list-item>
          <list-item>
            <p>Paraneoplastic syndromes</p>
          </list-item>
          <list-item>
            <p>Squamous cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Basal cell carcinoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23184.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis is related to the specific dermatological disease that is causing hyperkeratosis. Hyperkeratosis usually improves with treatment, but some cases may become persistent.</p>
      </sec>
      <sec id="article-23184.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Psychosocial distress can be elicited by the cosmetic appearance of hyperkeratosis, especially in exposed areas such as the face, scalp, and neck. Another complication that can occur is scarring secondary to the traumatic manipulation of the lesions by the patient. Clinicians&#x000a0;must educate patients on the necessity&#x000a0;of using the prescribed topical medications and refrain from manipulating the lesions.</p>
      </sec>
      <sec id="article-23184.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Dermatological consultation should be always considered in difficult cases or when therapy is not satisfactory. Pathological consultation should also be considered when skin biopsy can help in the diagnosis.</p>
      </sec>
      <sec id="article-23184.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated that basic skincare measures such as hygiene, hydration, exfoliation are important to maintain functional skin even in the affected areas. Instructions for the other precautions should be given based on the specific dermatological diagnosis.</p>
      </sec>
      <sec id="article-23184.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interaction with the patient and healthcare personnel involved in clinical care is essential for a correct diagnosis and follow-up. Clinicians should inform&#x000a0;patients about the diagnosis and expectations of treatment success. Depending on the final diagnosis, the treatment may require time and can be frustrating if it requires multiple months and repetitive follow-up reviews in the clinic.&#x000a0;The clinician&#x000a0;is encouraged to use a stepwise approach to hyperkeratosis.</p>
        <p>The initial evaluation must be very accurate, and a skin biopsy should be performed in the correct setting, and treatment can be started as soon as the diagnosis is clear to avoid mistreatment and disease exacerbation. Initial treatment usually consists of emollients, topical keratolytics, and re-evaluation. If&#x000a0;there is no response to a topical trial, the clinical setting should be re-evaluated, and the patient must always be informed&#x000a0;about other treatment options. Depending on the diagnosis, therapy can include corticosteroids,&#x000a0;retinoids, topical anti-inflammatories, vitamin-D derivatives, phototherapy, and laser treatment. It is important to always consider the possibility of a dermatology referral&#x000a0;for those that do not respond to treatment.</p>
        <p>The nursing personnel has a significant&#x000a0;role in counseling and monitoring patient progression. Pharmacists are frequently involved in patient care being sometimes the first to evaluate the lesion before medical referral. During follow-up, the pharmacist can be a helpful reference for the patient and may be asked for counseling or&#x000a0;for administration instructions. An interprofessional team approach is encouraged for optimal patient results.</p>
      </sec>
      <sec id="article-23184.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23184&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23184">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/hyperkeratosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23184">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23184/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23184">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23184.s18">
        <fig id="article-23184.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Psoriasis, on the Back Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="psoriasis__SV2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23184.s19">
        <fig id="article-23184.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Skin histology Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="673-20016" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23184.s20">
        <fig id="article-23184.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Histological Slide of Cutaneous Squamous Cell Carcinoma. Tumors classically consist of atypical keratinocytes with abundant eosinophilic or pink, glassy cytoplasm. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="673-20019" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23184.s21">
        <fig id="article-23184.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Hyperkeratosis of the skin Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="673-20018" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23184.s22">
        <title>References</title>
        <ref id="article-23184.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vastarella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fabbrocini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sibaud</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.</article-title>
            <source>Drug Saf</source>
            <year>2020</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>395</fpage>
            <page-range>395-408</page-range>
            <pub-id pub-id-type="pmid">31981081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carr</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Fiala</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Painful nipple hyperkeratosis secondary to vemurafenib.</article-title>
            <source>Dermatol Ther</source>
            <year>2017</year>
            <month>May</month>
            <volume>30</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28211633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heath</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sidbury</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of nutritional deficiency.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>417</fpage>
            <page-range>417-22</page-range>
            <pub-id pub-id-type="pmid">16914997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Setyadi</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Strasswimmer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Follicular eruption on arms and legs. Phrynoderma.</article-title>
            <source>Arch Dermatol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>144</volume>
            <issue>11</issue>
            <fpage>1509</fpage>
            <page-range>1509-14</page-range>
            <pub-id pub-id-type="pmid">19015431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maronn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Esterly</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Phrynoderma: a manifestation of vitamin A deficiency?... The rest of the story.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2005</year>
            <season>Jan-Feb</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-3</page-range>
            <pub-id pub-id-type="pmid">15660900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weedon</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The lichenoid tissue reaction.</article-title>
            <source>Int J Dermatol</source>
            <year>1982</year>
            <month>May</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>203</fpage>
            <page-range>203-6</page-range>
            <pub-id pub-id-type="pmid">6212557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rice</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <chapter-title>Epidermolytic Hyperkeratosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">31335043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vahlquist</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>T&#x000f6;rm&#x000e4;</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Inherited Nonsyndromic Ichthyoses: An Update on Pathophysiology, Diagnosis and Treatment.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-66</page-range>
            <pub-id pub-id-type="pmid">28815464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zirwas</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Acquired ichthyosis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>647</fpage>
            <page-range>647-56</page-range>
            <pub-id pub-id-type="pmid">17010746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hepper</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anadkat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cornelius</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.</article-title>
            <source>Arch Dermatol</source>
            <year>2012</year>
            <month>May</month>
            <volume>148</volume>
            <issue>5</issue>
            <fpage>628</fpage>
            <page-range>628-33</page-range>
            <pub-id pub-id-type="pmid">22431713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mateus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spatz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Escudier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Dermatologic symptoms associated with the multikinase inhibitor sorafenib.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>299</fpage>
            <page-range>299-305</page-range>
            <pub-id pub-id-type="pmid">19028406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Safi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Swami</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ginader</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Milhem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zakharia</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review.</article-title>
            <source>Cancers (Basel)</source>
            <year>2019</year>
            <month>Dec</month>
            <day>05</day>
            <volume>11</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">31817473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellis</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Vierra</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Millsop</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kiuru</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>1130</fpage>
            <page-range>1130-1143</page-range>
            <pub-id pub-id-type="pmid">32360716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macdonald</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Golitz</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>LoRusso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sekulic</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-18; quiz 219-20</page-range>
            <pub-id pub-id-type="pmid">25592338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ensslin</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>708</fpage>
            <page-range>708-720</page-range>
            <pub-id pub-id-type="pmid">23981682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brazzelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Grasso</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Borroni</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>12</issue>
            <fpage>1471</fpage>
            <page-range>1471-80</page-range>
            <pub-id pub-id-type="pmid">23611501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gerami</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guitart</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.</article-title>
            <source>Ann Oncol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1955</fpage>
            <page-range>1955-61</page-range>
            <pub-id pub-id-type="pmid">18550575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McLellan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ciardiello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Segaert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.</article-title>
            <source>Ann Oncol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>2017</fpage>
            <page-range>2017-26</page-range>
            <pub-id pub-id-type="pmid">26034039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Wanat</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Amaravadi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Fecher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Brose</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>McGettigan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Schuchter</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Seykora</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rosenbach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>1265</fpage>
            <page-range>1265-72</page-range>
            <pub-id pub-id-type="pmid">22609219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flaherty</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Infante</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Daud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kefford</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Sosman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schuchter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cebon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kudchadkar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burris</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Falchook</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Algazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Puzanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lebowitz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allred</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ouellet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Nov</month>
            <day>01</day>
            <volume>367</volume>
            <issue>18</issue>
            <fpage>1694</fpage>
            <page-range>1694-703</page-range>
            <pub-id pub-id-type="pmid">23020132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serup</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Atlas of Illustrative Cases of Tattoo Complications.</article-title>
            <source>Curr Probl Dermatol</source>
            <year>2017</year>
            <volume>52</volume>
            <fpage>139</fpage>
            <page-range>139-229</page-range>
            <pub-id pub-id-type="pmid">28288465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carlsen</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Sepehri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tattoo complaints and complications: diagnosis and clinical spectrum.</article-title>
            <source>Curr Probl Dermatol</source>
            <year>2015</year>
            <volume>48</volume>
            <fpage>48</fpage>
            <page-range>48-60</page-range>
            <pub-id pub-id-type="pmid">25833625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swigost</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Peltola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacobson-Dunlop</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Tattoo-related squamous proliferations: a spectrum of reactive hyperplasia.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>728</fpage>
            <page-range>728-732</page-range>
            <pub-id pub-id-type="pmid">29744912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Junqueira</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wanat</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Squamous neoplasms arising within tattoos: clinical presentation, histopathology and management.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>601</fpage>
            <page-range>601-606</page-range>
            <pub-id pub-id-type="pmid">28661073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saipoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A retrospective audit of lesion excision and rotation skin flap for the treatment of intractable plantar keratosis.</article-title>
            <source>Foot (Edinb)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>34</volume>
            <fpage>23</fpage>
            <page-range>23-27</page-range>
            <pub-id pub-id-type="pmid">29202430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23184.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Chiao</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Tzeng</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Plantar Hyperkeratosis in the Form of Recurrent Corns With Split-Thickness Sole Skin Graft.</article-title>
            <source>Ann Plast Surg</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>2S Suppl 1</issue>
            <fpage>S55</fpage>
            <page-range>S55-S58</page-range>
            <pub-id pub-id-type="pmid">29369100</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
